[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603035":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":35,"centralContacts":40,"locations":49,"responsibleParty":63,"collaborators":65,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":27,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":92,"whyStopped":27,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Institute of Liver and Biliary Sciences, India","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Three cycles of GCSF+ darbepoetin and standard medical treatment","EXPERIMENTAL","Patient randomize for Three cycle of GCSF+ darbepoetin together with standard medical treatment, G-CSF will be given at a dose of 5 μg\u002Fkg s\u002Fc at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30 based on hematological response and darbepoetin will be given s\u002Fc at dose of 40mcg once a week (total 4 doses) for 1 month. Second cycle of GCSF+ darbepoetin will be given after 1 month of completion of first cycle that is at month 3 and third cycle will be given 1 month after completion of 2nd cycle that is at 5th month. All patients will receive the standard medical treatment.",[13,14,15],"Drug: Gcsf","Drug: Darbepoetin","Other: Standard Medical Treatment",{"label":17,"type":18,"description":19,"interventionNames":20},"Single cycle of GCSF+ darbepoetin and standard medical treatment","ACTIVE_COMPARATOR","Patient randomize for Single cycle of GCSF+ darbepoetin together with standard medical treatment, G-CSF will be given at a dose of 5 μg\u002Fkg s\u002Fc at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30 based on hematological response and darbepoetin will be given s\u002Fc at dose of 40mcg once a week (total 4 doses) for 1 month. All patients will receive the standard medical treatment.",[13,14,15],[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Gcsf","G-CSF will be given at a dose of 5 μg\u002Fkg s\u002Fc at days 1, 2, 3, 4, 5 and then every third and 7th day till day 30",[17,9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Darbepoetin","Darbepoetin will be given s\u002Fc at dose of 40mcg once a week for 1 month",[17,9],{"type":6,"name":33,"description":33,"armGroupLabels":34,"otherNames":27},"Standard Medical Treatment",[17,9],[36],{"name":37,"affiliation":38,"role":39},"Dr. Shiv Kumar Sarin, DM","Institute of Liver & Biliary Sciences","PRINCIPAL_INVESTIGATOR",[41,46],{"name":42,"role":43,"phone":44,"phoneExt":27,"email":45},"Dr. Anupam Kumar, PhD","CONTACT","01146300000","dr.anupamkumar.ilbs@gmail.com",{"name":47,"role":43,"phone":44,"phoneExt":27,"email":48},"Fagun Sharma, M.Sc.","fagun.30sharma@gmail.com",[50],{"facility":38,"status":27,"city":51,"state":27,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"New Delhi","110070","India","IN",{"type":56,"coordinates":57},"Point",[58,59],77.2148,28.62137,{"lat":59,"lon":58},[62],{"name":42,"role":43,"phone":44,"phoneExt":27,"email":45},{"type":64,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR",[66],{"name":67,"class":68},"Indian Council of Medical Research","OTHER_GOV","100603035","national-collaborative-centre-for-hepatic-regenerative-medicine-nc-chrm-single-vs-repeated-cycle-of-granulocyte-colony-stimulating-factor-gcsf--darbepoetin-in-early-decompensated-cirrhosis-100603035",false,"NCT07131280","National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis","National Collaborative Centre for Hepatic Regenerative Medicine(NC-CHRM): To Study the Efficacy of Single vs Repeated Cycle of GCSF+ Darbepoetin in Long Term Transplant Free Management of Patient With Early Decompensated Cirrhosis","NC-CHRM","Inclusion Criteria:\n\n* Early decompensated cirrhosis patients with MELD \\\u003C16\n\nExclusion Criteria:\n\n* Patients with age less than 18 years or more than 65 years\n* Patients with Grade III ascites\n* CHILD C cirrhosis\n* Patients with a known focus of sepsis; spontaneous Bacterial Peritonitis (SBP)\n* variceal bleeding in past 3months\n* Hepatocellular Carcinoma (HCC) or other malignancy\n* Acute Kidney Injury (AKI) with serum Creatinine \\>1.5 mg\u002F dl, multi-organ failure, grade 3 or 4 Hepatic Encephalopathy (HE),\n* HIV seropositivity\n* Medically uncontrolled essential hypertension\n* Pregnancy\n* Viral etiology of liver disease\n* Co-existent Hepatitis B, Hepatitis C, HIV\n* Chronic kidney disease\n* Lack of informed consent","ALL","18 Years","65 Years",{"count":81,"type":82},110,"ESTIMATED","INTERVENTIONAL",[85],"NA","Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural repair. The goal is to develop safe, effective, and accessible treatments for patients who cannot undergo transplant.",[88],"Decompensated Cirrhosis",[90,91,29],"GCSF","Decompensated cirrhosis","NOT_YET_RECRUITING","2025-08-19",{"date":95,"type":96},"2025-08-20","ACTUAL",{"date":98,"type":82},"2025-09",{"date":100,"type":82},"2031-12",{"name":5,"class":6},1]